NCCN Updates Colon Cancer Guidelines
Posted on: Thursday, 22 December 2005, 09:00 CST
The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Colon Cancer Guidelines. The changes highlight cutting-edge developments in the treatment of colon cancer and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings.
The latest version of the NCCN Colon Cancer Guidelines include several major changes to recommended courses of treatment based on recent relevant clinical studies and changing practice patterns. One significant change is the recommendation that all first-line therapy for advanced or metastatic disease should include bevacizumab (Avastin) in the treatment regimen. The panel also added a new regimen, capecitabine (Xeloda) and oxaliplatin (Eloxatin) also known as CAPOX as a treatment option in first-line therapy.
In addition to changing treatment recommendations in advanced or metastatic disease, there are also new options in the adjuvant setting. The panel added new treatment regimens for Stage IIA patients, including capecitabine, 5-FU/leucovorin or 5-FU/leucovorin/oxaliplatin.
Also, a new section entitled "Principles of Pathologic Review" has been added to the NCCN Colon Cancer Guidelines to provide detailed information regarding issues such as adequate lymph node evaluation required for accurate staging and the sentinel lymph node and detection of micrometastasis by immunohistochemistry.
NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through a consensus-driven process with explicit review of the scientific evidence by multidisciplinary panels of expert physicians from NCCN member institutions. The most recent version of this and all the guidelines are available for free at www.nccn.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 19 of the world's leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN member institutions, NCCN develops resources that present valuable information to the numerous stakeholders throughout the health care delivery system. As the arbiter of high-quality cancer care, NCCN emphasizes the importance of and promotes continuous quality improvement, creating and publishing clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. NCCN programs include: Clinical Practice Guidelines in Oncology(TM), the NCCN Drugs & Biologics Compendium(TM), Treatment Guidelines for Patients, the Journal of the National Comprehensive Cancer Network (JNCCN), Cancer Resource Lines for Leukemia and Multiple Myeloma, educational conferences and symposia for clinicians, the Oncology Outcomes Database Project, the NCCN Oncology Research Program, NCCN Cancer Case Manager(TM), and collaborations with managed care organizations.
The NCCN member institutions are:
-- City of Hope Cancer Center
-- Dana-Farber/Partners CancerCare
-- Duke Comprehensive Cancer Center
-- Fox Chase Cancer Center
-- Huntsman Cancer Institute at the University of Utah
-- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
-- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University
-- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
-- Memorial Sloan-Kettering Cancer Center
-- H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida
-- Roswell Park Cancer Institute
-- St. Jude Children's Research Hospital / University of Tennessee Cancer Institute
-- Stanford Hospital & Clinics
-- University of Alabama at Birmingham Comprehensive Cancer Center
-- UCSF Comprehensive Cancer Center
-- University of Michigan Comprehensive Cancer Center
-- UNMC Eppley Cancer Center at The Nebraska Medical Center
-- The University of Texas M. D. Anderson Cancer Center
Source: Business Wire
Related Articles
- Cancer Treatment Guidelines for Diverse Asian Economies Use Model Developed at Fred Hutchinson Cancer Research Center
- Nationally Recognized Multiple Myeloma Expert Dr. David Vesole Joins the John Theurer Cancer Center at Hackensack University Medical Center
- Texas Oncology-Baylor Sammons Cancer Center Recognized for Highest Commitment to Clinical Research at ASCO
- NCCN 12th Annual Conference: Clinical Practice Guidelines in Oncology & Quality Cancer Care(TM) to Be Held March 14 - 18, 2007 in Hollywood, Florida
- Idera Pharmaceuticals Announces Formation of Oncology Clinical Advisory Board; Accomplished Physicians and Scientists in Cancer Drug Development
- The Endocrine Society Presents Clinical Practice Guidelines for Use of Growth Hormone in Adults and for Evaluation and Treatment of Androgen Deficiency in Men
- NCCN Announces Important Updates to Pancreatic Adenocarcinoma Clinical Practice Guidelines
- NCCN 11th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care(TM) Features Oncology Leadership
- Clinical Trial at Arkansas Cancer Research Center Demonstrates Breast Cancer Treatment Using RITA Medical Systems Radiofrequency Ablation Products Reduces Re-Excision Rates By 86%
- Clinical Practice Guidelines for Adults with Several Illnesses Could Have Undesirable Effects
 |
 |
User Comments (0)
RSS Feeds